Arcus Biosciences, Inc.
RCUS
$10.29
-$0.24-2.28%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 0.00 | -112.00M | -94.00M | -92.00M | -93.00M |
| Total Depreciation and Amortization | 2.00M | 3.00M | 3.00M | 2.00M | 2.00M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 13.00M | 14.00M | 14.00M | 15.00M | 16.00M |
| Change in Net Operating Assets | -148.00M | -37.00M | -23.00M | 101.00M | -19.00M |
| Cash from Operations | -133.00M | -132.00M | -100.00M | 26.00M | -94.00M |
| Capital Expenditure | 0.00 | -1.00M | -1.00M | -1.00M | 0.00 |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 137.00M | 33.00M | 52.00M | -28.00M | 63.00M |
| Cash from Investing | 137.00M | 32.00M | 51.00M | -29.00M | 63.00M |
| Total Debt Issued | 49.00M | -- | 0.00 | 47.00M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.00M | 142.00M | 3.00M | 2.00M | 3.00M |
| Repurchase of Common Stock | -- | -- | -5.00M | -1.00M | -1.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 52.00M | 142.00M | -2.00M | 48.00M | 2.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 56.00M | 42.00M | -51.00M | 45.00M | -29.00M |